Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30500503 | 1.00 | ALDH1A1 (0.33) | ALDH1A1KDM4EGAAKMT2AHSD17B10 | |
| SCHEMBL30500454 | 0.82 | ALDH1A1 (0.37) | ALDH1A1KDM4EKMT2AHSD17B10HPGD | |
| SCHEMBL14973641 | 0.82 | ALDH1A1 (0.37) | ALDH1A1KDM4EKMT2AHSD17B10HPGD | |
| SCHEMBL30500502 | 0.79 | ALDH1A1 (0.33) | ALDH1A1KDM4EGAAKMT2AHSD17B10 | |
| SCHEMBL22978545 | 0.79 | ALDH1A1 (0.37) | ALDH1A1KDM4EHPGD | |
| SCHEMBL30698353 | 0.77 | GAA (0.33) | ALDH1A1KDM4EGAAKMT2AHSD17B10 | |
| SCHEMBL29683105 | 0.73 | KDM4E (0.30) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL29682828 | 0.71 | KDM4E (0.31) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL29682901 | 0.71 | PDE4A (0.32) | — | |
| SCHEMBL3652695 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794525-A | Anticancer compounds | 加利福尼亚大学董事会 | 2024-03-29 | — | — | CN | disclosed |
| CN-116669727-A | Triazole-pyridinyl substituted azacyclohexylacetic acid compounds as LPA receptor antagonists | 唯久生物有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4196220-A1 | TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS | Viva Star Biosciences Limited (HK) | 2023-06-21 | — | — | EP | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022034568-A1 | TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS | VIVA STAR BIOSCIENCES LIMITED (CN) | 2022-02-17 | — | — | WO | disclosed |
| WO-2020116662-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | 第一三共株式会社 | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | ALDH1A1 3346/4885KDM4E 682/4885GAA 953/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | ALDH1A1 3346/4885KDM4E 682/4885GAA 953/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | ALDH1A1 3346/4885KDM4E 682/4885GAA 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.